AIM: £4.30 (-0.29) | Nasdaq: $29.02 (+0.41)

Search

EN
简
繁

About Us
Innovation Platform
Commercial Platform
News & Presentations
Financial Results
Shareholder Information
Career
- Career Opportunities

About Us

Overview
Corporate Information
Board of Directors
Senior Management
Contact Us

Innovation Platform

Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News

Commercial Platform

Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News

News & Presentations

Recent News
All RNS & Press Releases
Presentations & Publications

Financial Results

Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings

Shareholder Information

Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26

Career

Career Opportunities

Key Corporate Partnerships

Chi-Med
Innovation Platform
| Key Corporate Partnerships

AstraZeneca

In December 2011, Chi-Med entered into a global licensing, co-development, and commercialisation agreement regarding its highly selective c-Met inhibitor savolitinib with AstraZeneca.

Development costs for savolitinib in China are shared between Chi-Med and AstraZeneca, with Chi-Med continuing to lead the development in China. AstraZeneca leads and pays for the development of savolitinib for the rest of the world.

Chi-Med was entitled to receive an upfront payment as well as further payments contingent on the successful achievement of clinical development and ﬁrst sale milestones.

The agreement also contains possible future commercial sale milestones, a fixed royalty of on all sales in China and double-digit tiered royalties on all sales made outside of China.

Eli Lilly

In October 2013, Chi-Med entered into a licensing, co-development and commercialisation agreement in China with Lilly for fruquintinib, a selective inhibitor of the vascular endothelial growth factor receptor tyrosine kinase.

Under the terms of the agreement, the costs of future development of fruquintinib in China, to be carried out by Chi-Med, will be shared between Chi-Med and Lilly.

Chi-Med was entitled to receive an upfront payment and development and regulatory approval milestone payments. Should fruquintinib be successfully commercialised in China, Chi-Med would receive tiered royalties starting in the mid-teens percentage of net sales.

In 2018, we entered into non-exclusive global collaboration agreements with Junshi and Innovent to conduct safety run-in studies to evaluate the safety of fruquintinib or surufatinib in combination with PD-1 monoclonal antibodies being developed by Junshi (Tuoyi) and Innovent (Tyvyt)

Junshi

Under the global collaboration agreement with Junshi, we are responsible for leading development of, and bearing all costs related to, the initial development of the surufatinib and Tuoyi combination in China.

Junshi is responsible for leading development of, and bearing all costs related to, initial global development of the combination.

The agreement also contains possible future commercial sale milestones, a fixed royalty of on all sales in China and double-digit tiered royalties on all sales made outside of China.

Innovent

Under the global collaboration agreement with Innovent, we are to evaluate the combination of fruquintinib with Innovent’s Tyvyt,

a PD-1 monoclonal antibody approved in China in late 2018.

We and Innovent will share all initial development costs equally.

Contact Us
Disclaimer
Privacy Policy

© 2019Hutchison China MediTech Limited